Silence Therapeutics plc webcast live from Cowen Annual Health Care Conference

Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that on 17 January 2018 the European Patent

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics LON:SLN, commented on the post year update: “At our recent Capital Markets Day, Silence demonstrated that it is now has a powerful, reproducible and modular GalNAc-siRNA platform that

Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that it has sold part of its

Silence Therapeutics plc, LON:SLNa leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will today host a Capital Markets Day for analysts, investors and

Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that the US Patent and Trade Mark Office

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics LON:SLN, commented on the appointment: “Annalisa’s appointment is a significant moment in the transition of Silence to a fully-integrated biopharma company. Her extensive and broad experience in all aspects

Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced that the US Patent and Trade Mark Office yesterday

Stephen Parker, Non-Executive Chairman of Silence Therapeutics LON:SLN, commented: “This period has seen a strong performance from all parts of the Company, with improved management and controls adding to the excellent progress of the research group.

Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that the Company will host a Capital

Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that the US Patent and Trade Mark